Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeStance Health (LFST) Gains from Investment Securities (2021 - 2025)

Historic Gains from Investment Securities for LifeStance Health (LFST) over the last 5 years, with Q3 2025 value amounting to $209000.0.

  • LifeStance Health's Gains from Investment Securities rose 12589.84% to $209000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year increase of 37494.11%. This contributed to the annual value of -$1.4 million for FY2024, which is 7978.81% up from last year.
  • Latest data reveals that LifeStance Health reported Gains from Investment Securities of $209000.0 as of Q3 2025, which was up 12589.84% from $236000.0 recorded in Q2 2025.
  • In the past 5 years, LifeStance Health's Gains from Investment Securities ranged from a high of $47.0 million in Q2 2021 and a low of -$2.7 million during Q2 2023
  • Moreover, its 5-year median value for Gains from Investment Securities was $209000.0 (2025), whereas its average is $5.1 million.
  • In the last 5 years, LifeStance Health's Gains from Investment Securities skyrocketed by 1460000.0% in 2022 and then plummeted by 73556.09% in 2023.
  • Over the past 5 years, LifeStance Health's Gains from Investment Securities (Quarter) stood at $530000.0 in 2021, then decreased by 13.77% to $457000.0 in 2022, then crashed by 532.17% to -$2.0 million in 2023, then soared by 78.08% to -$433000.0 in 2024, then soared by 148.27% to $209000.0 in 2025.
  • Its Gains from Investment Securities stands at $209000.0 for Q3 2025, versus $236000.0 for Q2 2025 and $8.2 million for Q1 2025.